Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877274 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4871128 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3671252 | 0.90 | PDE4B (0.36) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3675821 | 0.90 | SSTR5 (0.40) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3676603 | 0.89 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3672015 | 0.89 | PDE4D (0.35) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4871505 | 0.88 | PDE4B (0.39) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3669754 | 0.88 | PDE4A (0.37) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4872615 | 0.88 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4879467 | 0.88 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825147-B2 | Inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-02 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | claimed |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | claimed |
| US-20080009535-A1 | Inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2008-01-10 | — | — | US | claimed |
| EP-1840123-A1 | Isoxazolines and their use as inhibitors of phosphodiesterase type-IV | Ranbaxy Laboratories Limited (IN) | 2007-10-03 | — | — | EP | claimed |
| EP-1663999-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES, LTD. (IN) | 2006-06-07 | — | — | EP | claimed |
| US-20050075383-A1 | Inhibitors of phophodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-07 | — | — | US | claimed |
| WO-2005021515-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-10 | — | — | WO | claimed |
| US-7825147-B2 | Inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-02 | — | — | US | disclosed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | disclosed |
| US-20080009535-A1 | Inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2008-01-10 | — | — | US | disclosed |
| EP-1840123-A1 | Isoxazolines and their use as inhibitors of phosphodiesterase type-IV | Ranbaxy Laboratories Limited (IN) | 2007-10-03 | — | — | EP | disclosed |
| EP-1663999-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES, LTD. (IN) | 2006-06-07 | — | — | EP | disclosed |
| US-20050075383-A1 | Inhibitors of phophodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-07 | — | — | US | disclosed |
| WO-2005021515-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009535-A1 | Inhibitors of phosphodiesterase type-IV | PDE4A, PDE3B, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4C 4/4885 |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | PDE4A 2/4885PDE4B 1/4885PDE4C 6/4885 |
| US-20050075383-A1 | Inhibitors of phophodiesterase type-IV | PDE7A, PDE4A, PDE4B | PDE4A 2/4885PDE4B 3/4885PDE4C 4/4885 |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | PDE4A 2/4885PDE4B 1/4885PDE4C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.